Contemporary Therapy of Femoropopliteal In-Stent Restenosis / Occlusion, 36-month Follow up Study.

Vascular and endovascular surgery Pub Date : 2024-10-01 Epub Date: 2024-05-13 DOI:10.1177/15385744241253170
Kenji Suzuki, Mitsuyoshi Takahara, Kazuki Tobita, Naoki Hayakawa, Shinsuke Mori, Yo Iwata, Kazunori Horie, Tatsuya Nakama
{"title":"Contemporary Therapy of Femoropopliteal In-Stent Restenosis / Occlusion, 36-month Follow up Study.","authors":"Kenji Suzuki, Mitsuyoshi Takahara, Kazuki Tobita, Naoki Hayakawa, Shinsuke Mori, Yo Iwata, Kazunori Horie, Tatsuya Nakama","doi":"10.1177/15385744241253170","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Drug-eluting devices improved outcomes of endovascular therapy (EVT) for femoropopliteal lesions, but mainly for de novo lesions. Endovascular therapy for in-stent restenosis/occlusion (ISR/O) is challenging, and large trials and long-term data are not well reported.</p><p><strong>Materials and methods: </strong>This study is a physician initiated, multicenter, and retrospective design. From 7 Japanese institutes, 3635 femoropopliteal cases were enrolled in the study. Among these, 346 cases of first ISR/O were studied. We defined drug-coated-balloon, drug-eluting stent, and covered stent as New devices. Balloon angioplasty and bare nitinol stent were included in the control group.</p><p><strong>Results: </strong>The propensity score matching extracted 112 pairs. At 12 months, the primary patency rate was 80.3% in the new device group and 52.7% in the control group, and there was a significant intergroup difference (<i>P</i> = .004). However, at 36 months, the rate was 43.3% vs 39.2%, with no significant difference (<i>P</i> = .090). No baseline characteristics had any significant interaction effect (all <i>P</i> > .05).</p><p><strong>Conclusions: </strong>The New devices were more effective than the control group for ISR/O at 1 year, but caught up at 3 years.</p>","PeriodicalId":94265,"journal":{"name":"Vascular and endovascular surgery","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vascular and endovascular surgery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/15385744241253170","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/5/13 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Drug-eluting devices improved outcomes of endovascular therapy (EVT) for femoropopliteal lesions, but mainly for de novo lesions. Endovascular therapy for in-stent restenosis/occlusion (ISR/O) is challenging, and large trials and long-term data are not well reported.

Materials and methods: This study is a physician initiated, multicenter, and retrospective design. From 7 Japanese institutes, 3635 femoropopliteal cases were enrolled in the study. Among these, 346 cases of first ISR/O were studied. We defined drug-coated-balloon, drug-eluting stent, and covered stent as New devices. Balloon angioplasty and bare nitinol stent were included in the control group.

Results: The propensity score matching extracted 112 pairs. At 12 months, the primary patency rate was 80.3% in the new device group and 52.7% in the control group, and there was a significant intergroup difference (P = .004). However, at 36 months, the rate was 43.3% vs 39.2%, with no significant difference (P = .090). No baseline characteristics had any significant interaction effect (all P > .05).

Conclusions: The New devices were more effective than the control group for ISR/O at 1 year, but caught up at 3 years.

股动脉支架内再狭窄/闭塞的当代疗法,36 个月随访研究。
背景:药物洗脱装置改善了股骨头病变血管内治疗(EVT)的疗效,但主要是针对新发病变。支架内再狭窄/闭塞(ISR/O)的血管内治疗具有挑战性,大型试验和长期数据尚未得到充分报道:本研究由医生发起,采用多中心和回顾性设计。来自日本 7 家医疗机构的 3635 例股骨头病例被纳入研究。其中研究了 346 例首次 ISR/O 病例。我们将药物涂层球囊、药物洗脱支架和覆盖支架定义为新设备。对照组包括球囊血管成形术和裸镍钛诺支架:倾向评分匹配提取了 112 对患者。12 个月时,新装置组的主要通畅率为 80.3%,对照组为 52.7%,组间差异显著(P = .004)。但在 36 个月时,新装置组和对照组的初次通畅率分别为 43.3% 和 39.2%,无明显差异(P = 090)。所有基线特征都没有明显的交互影响(P > .05):结论:与对照组相比,新设备在 1 年内对 ISR/O 的治疗效果更好,但在 3 年内则迎头赶上。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信